Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01492972|
Recruitment Status : Recruiting
First Posted : December 15, 2011
Last Update Posted : April 4, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer.
Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Radiation: Radiation Drug: Androgen Suppression Therapy||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||192 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||December 2025|
Active Comparator: Radiation Alone
Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
Experimental: Radiation + Androgen Suppression
Androgen Suppression Therapy x 6 months + Radiation
Drug: Androgen Suppression Therapy
Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
Other Name: leuprolide, goserelin, buserelin, or triptorelin
- Morbidity Outcomes [ Time Frame: after the initial 100 patients have had a median follow up of at least three years and then every year. ]
To determine if androgen suppression along with radiation therapy will result in a higher freedom from failure (FFF) than radiation therapy without androgen suppression.
Freedom from failure (FFF): The events for FFF will be the first occurrence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (PSA ≥ 2 ng/ml over the current nadir PSA) (45) discounting bounces per investigator discretion, or the start of salvage therapy including androgen suppression
- Frequency and severity of grade 2 or higher GU and GI toxicity [ Time Frame: At 6 months ]Assessment of grade 2 or higher GU and GI toxicity using CTCAE 4.0 criteria
- Frequency and severity of GI and GU toxicity [ Time Frame: At 3 years ]
- Incidence of quality of life issues [ Time Frame: At completion of radiation therapy ]
- Incidence of Freedom from biochemical failure (FFBF) [ Time Frame: At 5 years ]
- Incidence of clinical failure: local and/or distant [ Time Frame: At 5 years ]
- Incidence of salvage Androgen Suppression use (SAD) [ Time Frame: At 5 years ]
- Incidence of progression free survival: using clinical, biochemical and SAD as events [ Time Frame: At 5 years ]
- Incidence of overall survival [ Time Frame: At 5 years ]
- Incidence of disease-specific survival [ Time Frame: At 5 years ]
- Correlate pathologic and radiologic findings with outcomes [ Time Frame: At 5 years ]
- Correlate PSA and free PSA levels with outcomes [ Time Frame: At 5 years ]
- Correlate testosterone levels and variation with proton therapy and outcomes [ Time Frame: At 5 years ]
- Prospectively collect information that will help to define dose-volume relationships of normal structures with acute and chronic toxicity [ Time Frame: At 3 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed prostate adenocarcinoma (within 365 days of randomization) at intermediate risk for reoccurrence determined by at least one of the following: Gleason Score 7, PSA > = 10 and < = 20, T stage T2b - T2c
- Clinical stages T1-T2c N0 M0 as staged by the treating investigator. (AJCC Criteria 7th Ed.- appendix III).
- Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range of 2-7. > 6 cores are strongly recommended.
- PSA values < = 20 ng/ml within 90 days prior to randomization. Obtained prior to biopsy or at least 21 days after prostate biopsy.
- ECOG performance status 0-1 (appendix II) assessed within 90 days of randomization.
- Patients must sign IRB approved study specific informed consent.
- Patients must complete all required pre-entry tests listed in section 4.0 within the specified time frames.
- Patients must be able to start treatment within 56 days of randomization.
- Patients must be at least 18 years old.
- For brachytherapy, an IPSS ≤ 21, or ≤ 17 if patient is on medications to improve urination.
- For brachytherapy, prostate volume must be less than 55cc prior to AS.
- Pelvic lymph nodes > 1.5 cm in greatest dimension unless the enlarged lymph node is biopsied and negative.
- Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.
- Previous pelvic radiation for prostate cancer.
- Previous androgen suppression therapy for prostate cancer.
- Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed).
- Prior systemic chemotherapy for prostate cancer.
- History of proximal urethral stricture requiring dilatation.
- Current and continuing anticoagulation with warfarin sodium (Coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (Plavix), or equivalent (unless it can be stopped to manage treatment related toxicity or to have a biopsy if needed).
- Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study).
- Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).
- History of myocardial infarction within the last 6 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01492972
|Contact: Matthew Moroccoemail@example.com|
|United States, Arizona|
|Scottsdale, Arizona, United States, 85259-5499|
|Contact: : Clinical Trials Office - All Mayo Clinic Locations 855-776-0015 (toll free)|
|United States, Illinois|
|Northwestern Medicine Chicago Proton Center||Recruiting|
|Warrenville, Illinois, United States, 60555|
|Contact: Don Smith, MS, CCRC 630-933-7820 firstname.lastname@example.org|
|Principal Investigator: William Hartsell, MD|
|United States, Oklahoma|
|Oklahoma Proton Center||Recruiting|
|Oklahoma City, Oklahoma, United States, 73142|
|Contact: Jenny Washington, BSRT(T), CMD 405-773-6700 email@example.com|
|Principal Investigator: John Chang, MD|
|United States, Virginia|
|Hampton University Proton Therapy Institute||Recruiting|
|Hampton, Virginia, United States, 23666|
|Contact: Donna Sternberg, RN, BSN, OCN 757-251-6839 Donna.Sternberg@hamptonproton.org|
|Principal Investigator: Christopher Sinesi, MD|
|Principal Investigator:||Carlos Vargas, MD||Proton Collaborative Group|
|Responsible Party:||Proton Collaborative Group|
|Other Study ID Numbers:||
|First Posted:||December 15, 2011 Key Record Dates|
|Last Update Posted:||April 4, 2023|
|Last Verified:||April 2023|
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Male Urogenital Diseases
Fertility Agents, Female
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Hormones, Hormone Substitutes, and Hormone Antagonists
Contraceptive Agents, Female
Contraceptive Agents, Hormonal